# A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

> **NCT05691712** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 257 (actual)

## Conditions studied

- Diabetes Type 2
- Diabetes Mellitus
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05691712
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-05
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05691712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05691712, "A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05691712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*